For decades, we have leveraged our world-class expertise in medicinal chemistry and biology to discover, develop and deliver medicines that offer patients new treatment options.

NAVIGATE TO
RESOURCES

Haematology

Haematology is central to the identity of Incyte. We are a leader in the discovery and development of therapies for patients with myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). Building on this legacy, we are developing mutation-specific targeted therapies across the full MPN spectrum that have the potential to transform treatment for patients.

Oncology

Despite progress, cancer continues to be a leading cause of death worldwide, impacting millions of people. Given the significant unmet medical need, we are advancing research in areas where we believe we can have the greatest impact.

Our focus is on novel biologic targets and pathways in high incidence cancers, and we are exploring both single agents and combinations of targeted and immuno-therapies from both within and beyond our portfolio.

Resources

FOR HEALTHCARE PROFESSIONALS

Global Medical Information

Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please visit incyteglobalmedicalinformation.com.

Please call Incyte European Medical Information department on 00 800 00027423 or Direct Dial for the UK only +44 1423 533 517 or email EU Incyte Call Center eumedinfo@incyte.com. For UK general enquiries, please email UK_enquiries@incyte.com.

UK Adverse Event Reporting Information:

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Incyte by calling 00 800 00027423.

Ireland Adverse Event Reporting Information:

Adverse events should be reported. Reporting forms and information can be found at: HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Incyte by calling 1800 456 748.